AstraZeneca will pay Dizal Pharmaceutical $600 million up front to acquire global rights to Sunvozertinib, also marketed as Zegfrovy, Dizal said in a filing to the Shanghai stock exchange on Tuesday.
Sunvozertinib is approved in the United States and China for use in adults with locally advanced or metastatic non-small cell lung cancer. Non-small cell lung cancer represents about 77% of all lung cancer cases, the filing noted.
The agreement grants AstraZeneca the worldwide development and commercialization rights for the drug. Under the terms disclosed, Dizal is eligible for the $600 million upfront payment and may receive up to $900 million more in payments that depend on clinical development milestones and sales-related targets.
The clinical evidence cited in Dizal's disclosure includes a late-stage, multinational trial enrolling 324 patients. That study reported a median progression-free survival of 10.3 months for patients treated with Sunvozertinib versus 7.5 months for those receiving chemotherapy.
In a statement included in the filing, Dave Fredrickson, Executive Vice President of the Oncology Haematology Business Unit at AstraZeneca, said: "With this agreement, we will bring a differentiated, oral targeted treatment to these patients with limited options across the globe."
The transaction structure leaves Dizal positioned to benefit immediately from the upfront cash payment while also retaining potential upside tied to future regulatory and commercial outcomes. AstraZeneca assumes responsibility for taking the drug forward internationally, encompassing further development activities and the commercialization pathway.
Context and implications
The deal moves global stewardship of an approved oncology therapy from its Chinese originator to a multinational pharmaceutical company. The arrangement channels near-term capital to Dizal and shifts long-term development and sales exposure to AstraZeneca.
What remains unchanged in the filing
- The upfront cash payment is $600 million.
- Contingent payments could total up to $900 million based on clinical and sales milestones.
- The key clinical result reported is median progression-free survival of 10.3 months versus 7.5 months for chemotherapy in a 324-patient trial.